You are here

  • Home
  • Archive
  • Volume 12, Issue 11
  • Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

Article metrics

Article menu
Health economics
Original research
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

 

Online download statistics by month:

Online download statistics by month: November 2022 to April 2024

AbstractFullPdf
Nov 2022536540105
Dec 202249449582
Jan 202338237956
Feb 202326726765
Mar 202325625341
Apr 202327427380
May 2023969143
Jun 2023767127
Jul 2023595827
Aug 2023807430
Sep 2023303028
Oct 2023413829
Nov 2023615633
Dec 2023353620
Jan 2024454530
Feb 2024333221
Mar 20244637106
Apr 2024211527
Total28322790850